Drug Profile
Research programme: small molecule therapeutics - InventisBio
Latest Information Update: 28 Apr 2023
Price :
$50
*
At a glance
- Originator InventisBio
- Class Antineoplastics; Hepatoprotectants; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Lung cancer; Non-alcoholic steatohepatitis
Most Recent Events
- 28 Apr 2023 No recent reports of development identified for preclinical development in Non-alcoholic-steatohepatitis in China
- 28 Apr 2023 No recent reports of development identified for preclinical development in Non-alcoholic-steatohepatitis in USA
- 28 Jun 2021 No recent reports of development identified for preclinical development in Lung-cancer in China